Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CYBB | P04839 | 1/20 | 0.44 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.44 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.44 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.44 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28112415 | 0.79 | CHKA (0.80) | DHFRCHKAADRB2NCF1PLD1 | |
| SCHEMBL11150401 | 0.79 | HRH4 (0.59) | HRH4HTR6HRH3 | |
| SCHEMBL3440171 | 0.76 | CHKA (0.52) | DHFRCHKAADRB2NCF1PLD1 | |
| SCHEMBL3439981 | 0.76 | CHKA (0.61) | DHFRCHKAADRB2NCF1PLD1 | |
| SCHEMBL12696742 | 0.75 | CHKA (0.46) | HRH4DHFRCHKAHTR6ADRB2 | |
| SCHEMBL128037 | 0.75 | HRH4 (0.59) | HRH4 | |
| SCHEMBL10453209 | 0.75 | HRH4 (0.59) | HRH4 | |
| SCHEMBL8217931 | 0.74 | CHKA (0.64) | DHFRCHKAADRB2NCF1PLD1 | |
| SCHEMBL16473503 | 0.71 | DHFR (0.48) | HRH4DHFRCHKAHTR6ADRB2 | |
| SCHEMBL18590696 | 0.71 | CHKA (0.67) | CHKAADRB2NCF1PLD1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-7858782-B2 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, CAMKK2, BAZ1A | HRH4 2127/4885DHFR 1828/4885CHKA 409/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | HRH4 2057/4885DHFR 2833/4885CHKA 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.